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84 Poster Session-Ithat the continued presence of CD4 T cells after HSCT is required
for the development of CD8memory. Upon investigating the mech-
anism(s) of memory loss, we observed an accelerated contraction of
tumor-reactive CD8 cells in the CD4-depleted mice. This acceler-
ated loss of tumor-reactive CD8 cells correlated with increased per-
centages of annexin-V1 pre-apoptotic CD8 cells during the
contraction phase (day 21 after HSCT). A significant proportion
of the annexin-V1 CD8 cells co-expressed programmed death re-
ceptor-1 (PD-1), had an effector phenotype (CD62L-CD441),
and expressed diminished levels of the receptors for IL-7 and IL-
15. These data suggest that PD-1/PD-L1 interactions may play
a role in the loss of CD8 memory. Together, these results show
that CD41 cells can both promote and inhibit anti-tumor responses.
These observations should help us design immunotherapeutic
approaches that can generate ‘‘optimal’’ acute anti-tumor reactivity
after HSCT with development of long-term immunity.230
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Stem cell transplantation from aHLA-compatible sibling donor is
an adoptive immunotherapy for cytokine-resistant, metastatic renal
cancer (RCC). However, the recent introduction of several targeted
therapy compounds has reduced the interest in this therapeutic strat-
egy. We have reanalyzed our transplant series with the aim to detect
long-term benefit form allografting. From February 1999 to May
2005, 25 patients with cytokine-refractory RCC received a re-
duced-intensity allograft from an HLA-id sibling donor. Median
age was 53 years; most (24) had clear-cell histology. Median number
of previous treatments was 1 (0–3). Median days from diagnosis to
allograft were 822. All patients received a thiotepa, fludarabine,
and cyclophosphamide conditioning regimen, and a cyclosporine-
based GVHD prophylaxis. Six patients received DLI at escalating
doses for progressing or non-responding disease. One-year-OS
was 48% (95% CI: 28–68), and 3y-OS was 20% (95% CI: 4–36).
At a median observation time of 65 months, 5 patients are alive,
one in CR, one in VGPR, and three with stable disease.We have an-
alyzed the correlation of the following variables with survival: age at
transplant, time from diagnosis to transplant, serum calcium cor-
rected for albumin levels, lactate dehydrogenase (LDH), C-reactive
protein (CRP), haemoglobin level before transplantation, Karnofsky
performance status, number of CD341/kg infused, number of
CD31/kg infused, progressive disease at 190 after transplant, oc-
currence of acute (any grade) or chronic GvHD. At multivariate
analysis, CRP value before transplant, number of CD341 infused
cells and disease status at 190 significantly correlated with survival.
Survival of patients at favourable/intermediate-risk according to the
MSKCC score that underwent allografting was better in comparison
to the survival predicted by historical controls. We conclude that
transplantation is able to induce long-term disease control in
twenty percent of cytokine-refractory RCC patients. It is unknown
if relapse or PD after targeted therapy will be susceptible to
allograft-mediated GVT effect. The place of allografting in the
treatment of metastatic RCC, alone or in combination with targeted
therapies, needs reappraisal.231
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Autologous hematopoetic stem cell transplantation (HDT) has
been utilized as consolidative therapy for pediatric patients with
some encouraging improvement in survival. We hypothesize thatby intensifying therapy which poor prognosis patients currently
receive, it is possible to reduce the risk of relapse after HDT and
the morbidity and mortality will be acceptable. Phase I pediatric
studies of topotecan demonstrated activity against solid tumors.
The dose-limiting toxicity of Phase I studies has been hematopoietic
suppression. The use of hematopoietic stem cell support following
a topotecan-containing preparative regimen will allow utilization
of topotecan in combination with established chemotherapeutic
agents. Patients were assigned to receive topotecan at 2 mg/m2
continuous infusion in combination with fixed doses of busulfan
andmelphalan (B-M-T). In this study, the primary outcome variable
is to evaluate the toxicity of combinedHDTwith B-M-T. Secondary
objective is to analyze the engraftment and outcomes.
Results:Thirteen patients age 2–18 year old (median5 5.4) were
treated on B-M-T-protocol. Seven patients were diagnosed with
neuroblastoma (NBL),Wilms tumor (n5 2), PNET (n5 2), -rhab-
domyosarcoma (RBS) and Ewing sarcoma (each n 5 1). Eight pa-
tients were in CR, five in PR. There were no deaths in the first100
day postHDT.There was 1 admission (1day) to ICU for observation
only. Eleven patients developed grade 1–2 and 2 patients grade 3
liver toxicity (transaminitis and bilirubin elevation), all patients de-
veloped grade 2- 3 mucositis, five patients had grade 2 diarrhea,
one patient developed grade 3 respiratory toxicity, 7 patients had
metabolic toxicities grade 1–2. All patients engrafted. Patients
achieved ANC . 500 on day 8–15 (median 12), platelets .25,000
on day 9 -22 (median 16), no RBC transfusions were required after
day7–25, (median 16.2). Overall 1 1⁄2 year survival rate is 87 % (11
out of 13 patients are alive); event free survival is 78%.Three patients
had recurrent disease: 2 patients with PNET (both patients expired)
and 1 pt with NBL (alive).
Conclusions: Analysis of the preliminary data suggests that B-M-
T regimen in the context of HDT was tolerated without unexpected
or severe toxicity and allowed prompt transition to radiation and/or
maintenance therapy. Further studies are needed to document the
survival benefit of consolidation with B-M-T regimen in children
with high risk solid tumors.232
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Despite continuous advances in the treatment of mBcr, some pa-
tients have very poor outcome. Over the last period, we have inves-
tigated allogeneic immunotherapy as a possibility for tumor control
in patients with advanced mBrC. We have treated 31 pts with Allo
SCT in 2 successive clinical trials. All pts (age: 43 (27–57)) under-
went ASCT after the same RIC (Fludarabin (150mg/m2), Busulfan
(8mg/kg) and Thymoglobulin (2,5mg/kg) or TLI (1 Cgy)) from
a HLA-identical sibling (BM: 13%; PBSC: 87%) followed by CSA.
Prior to ASCT a median of 3 lines of treatment (1–7) have been ad-
ministered over a period of 57 months (6–143).15 (48%) pts under-
went autologous SCT at a median time of 15 months (1–99) prior to
ASCT. All pts were measurable and had a median of 2 metastatic
sites (1–4) (liver:72%, bone:50%, lung:22% and brain:11%). At
transplant : 17 (55%), 10 (32%) and 4 (13%) pts had progressive
(PD), stable disease (SD) and partial response (PR) respectively.
All patients engrafted. The cumulative incidences of grade 2–4
aGVHD and cGVHD were 42% (25–59) and 62% (45–79) respec-
tively. Of note, none of the 31 pts died from TRM. Seven patients
achieved an objective response (CR 5 1; PR 5 6) at a median of
60 days (30–150) for a 24 % (9–39) OR cumulative incidence.
Eventually all pts but 3 progressed at a median of 310 days (120–
560) post transplant. Four pts are alive at median of 23 months
(21–30) post transplant for a 2-year overall survival (OS) probabil-
ity of 29% (16–47)). Results are dramatically different in regards to
disease status at time of transplant. While outcome was uniformly
poor for pts with PD (OR 5 0; 2 year OS probability: 6% (1–27)),
